RESUMEN
OBJECTIVES: Alkaptonuria is a rare autosomal recessive genetic disorder resulting from the deficiency of homogentisate 1,2 dioxygenase (HGD), the third enzyme in the tyrosine degradation pathway. Homogentisic acid produced in excess oxidizes into ochronotic pigment polymer. Accumulation of this pigment in various tissues leads to systemic disease. METHODS: Clinical, laboratory, molecular findings and treatment characteristics of 35 patients followed up in Ege University Pediatric Nutrition, and Metabolism Department with the diagnosis of alkaptonuria were evaluated retrospectively. RESULTS: Twenty-four males (68.57%) and 11 females (31.42%) with a confirmed diagnosis of alkaptonuria from 32 different families were included in the study. We identified 11 different genetic variants; six of these were novel. c.1033C>T, c.676G>A, c.664G>A, c.731_734del, c.1009G>T, c.859_862delins ATAC were not previously reported in the literature. 24 (68.57%) patients only adhered to a low-protein diet in our study group. Seven (20%) patients initiated a low protein diet and NTBC therapy. Mean urinary HGA decreased by 88.7% with nitisinone. No statistical changes were detected in urinary HGA excretion with the low protein diet group. CONCLUSIONS: In our study, alkaptonuria patients were diagnosed at different ages, from infancy to adulthood, and progressed with other systemic involvement in the follow-up. Since the initial period is asymptomatic, giving potentially effective treatment from an early age is under discussion. Raising disease awareness is very important in reducing disease mortality and morbidity rates.
Asunto(s)
Alcaptonuria , Adulto , Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Alcaptonuria/genética , Niño , Femenino , Estudios de Seguimiento , Homogentisato 1,2-Dioxigenasa/genética , Homogentisato 1,2-Dioxigenasa/metabolismo , Ácido Homogentísico/metabolismo , Humanos , Masculino , Estudios Retrospectivos , TirosinaRESUMEN
Alkaptonuria is characterized by the accumulation of homogentisic acid (HGA), part of which is excreted in the urine but the excess HGA forms a dark brown ochronotic pigment that deposits in the connective tissue (ochronosis), eventually leading to early-onset severe arthropathy. We analyzed a cohort of 48 Russian AKU families by sequencing all 14 exons (including flanking intronic sequences) of the homogentisate 1,2-dioxygenase gene (HGD) and Multiplex Ligation-dependent Probe Amplification (MLPA) analysis. Nine novel likely pathogenic HGD variants were identified, which have not been reported previously in any other country. Recently, Bychkov et al. [1] reported on the variant spectrum in another cohort of 49 Russian AKU patients. Here we summarize complete data from both cohorts that include 82 Russian AKU families. Taken together, 31 different HGD variants were found in these patients, of which 14 are novel and found only in Russia. The most common variant was c.481G>A (p.(Gly161Arg)), present in almost 54% of all AKU alleles.
Asunto(s)
Alcaptonuria , Artropatías , Ocronosis , Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Alcaptonuria/genética , Exones , Homogentisato 1,2-Dioxigenasa/genética , Ácido Homogentísico/orina , Humanos , Artropatías/genética , Ocronosis/epidemiología , Ocronosis/genéticaRESUMEN
ABSTRACT: This study aimed to determine the patient characteristics and clinical presentation of Alkaptonuria cases reported by the Biochemical Genetics Lab.An observational study was conducted at the Biochemical Genetics Lab. Alkaptonuria patients were diagnosed based on the homogentisic acid peak in urine and their demographics and clinical data collected from to 2013 to 2019. Clinical history related to joint diseases, ochronotic presentation, and urine darkening on standing was collected.During 7 years, 21 Alkaptonuria cases were reported from BGL; mean age 19.4â±â24.5âyears (range 0.2-66âyears) and male to female ratio of 2:1. Of the total, only 9 were adults (mean age, 44â±â12âyears). Most adult patients had musculoskeletal involvement, with joint pain (nâ=â9) and ochronotic pigmentation (nâ=â6), whereas all patients presented with a history of urine darkening on standing (21/21 cases).The high prevalence of musculoskeletal involvement observed in patients with albuminuria is likely to be missed by physicians unless specifically tested for in such cases.
Asunto(s)
Alcaptonuria , Artropatías , Ocronosis , Adolescente , Adulto , Anciano , Alcaptonuria/complicaciones , Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Niño , Preescolar , Estudios Transversales , Femenino , Humanos , Lactante , Artropatías/complicaciones , Artropatías/epidemiología , Masculino , Persona de Mediana Edad , Sistema Musculoesquelético , Ocronosis/complicaciones , Ocronosis/epidemiología , Pakistán/epidemiología , Adulto JovenRESUMEN
Alkaptonuria (AKU) is an inborn error of metabolism caused by the deficiency of homogentisate 1,2-dioxygenase (HGD) as a result of a defect in the HGD gene. HGD enzyme deficiency results in accumulation of homogentisic acid (HGA) in the body, which in turn leads to multisystemic clinical symptoms. The present study aimed to investigate the presenting symptoms, age at diagnosis, and clinical and genetic characteristics of AKU patients followed-up in different centers in Turkey. In this cross-sectional, multicenter, descriptive study, medical records of 66 AKU patients were retrospectively evaluated. Patients' data regarding demographic, clinical and genetic characteristics were recorded. HGD database (http://hgddatabase.cvtisr.sk/) was used to identify HGD gene variants. Of the patients, 37 (56.1%) presented with isolated dark urine and 29 (43.9%) were diagnosed based on the clinical symptoms or family screening. One of these patients was on follow-up for 2 years due to Parkinsonism and was diagnosed with AKU on further analyses. Signs of ochronosis such as joint pain, low back pain and renal stones developed in childhood in 7 patients. Eight patients were diagnosed with depression via psychiatric evaluation. There were 14 (21.2%) patients operated on for ochronosis. The most frequent mutation observed in the patients was c.175delA, which was followed by c.674G > A and c.1007-2A > T mutations. Four novel mutations (c.189G > A, c.549+1G > T, c.1188+1G > A, and c.334 T > G) were identified in the patients included in the study. In addition to the known signs such as dark urine and skin pigmentation, symptoms involving different systems such as neurological findings and depression can also be encountered in AKU patients. The presence of a change in urine color needs to be questioned in patients presenting with different symptoms such as arthralgia/arthritis, renal stones or low-back pain, particularly in childhood, when skin ochronosis is not pronounced, and further examination should be performed.
Asunto(s)
Alcaptonuria/genética , Homogentisato 1,2-Dioxigenasa/genética , Fenotipo , Adolescente , Adulto , Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Niño , Preescolar , Depresión/epidemiología , Diagnóstico Diferencial , Diagnóstico Precoz , Femenino , Humanos , Lactante , Cálculos Renales/epidemiología , Masculino , Persona de Mediana Edad , Mutación , Ocronosis/epidemiología , TurquíaRESUMEN
Background Alkaptonuria (OMIM: 203500) is an inborn error of metabolism due to homogentisate 1,2-dioxygenase homogentisic acid 1,2 dioxygenase (HGD) enzyme deficiency. Due to the enzyme deficiency, homogentisic acid cannot be converted to maleylacetoacetate and it accumulates in body fluids. Increased homogentisic acid is converted to benzoquinones, the resulting benzoquinones are converted to melanin-like pigments, and these pigments are deposited in collagen - this process is called ochronosis. In patients with alkaptonuria, the urine is darkened, which is misinterpreted as hematuria, the incidences of renal stones, arthritis and cardiac valve calcification are increased, and spontaneous tendon ruptures, prostatitis and prostate stones can be encountered. The present study aimed to evaluate the HGD gene mutations in 14 patients with alkaptonuria. Methods Fourteen patients diagnosed with alkaptonuria and followed up from 1990 to 2014 were retrospectively evaluated. Their demographic, clinical and treatment-related data were retrieved from hospital files. For mutation analysis, genomic DNAs of the patients were isolated from their peripheral blood samples. Variations in the HGD gene were scanned on the HGD-mutation database (http://hgddatabase.cvtisr.sk). Results Among 14 patients, the female/male ratio was 1/1 and the median age was 9 years (range, 6-59 years). All patients were symptomatic at their first visit and the most common symptom was dark urine (71%) followed by arthralgia. Independent of the urinary homogentisic acid concentrations, patients with the presenting symptom of arthralgia were elder. Nine different mutations including p.Ser59AlafsX52, p.Gly161Arg, p.Asn219Ser, p.Gly251Asp, p.Pro274Leu, p.Arg330Ser, p.Gly372Ala, c.656_657insAATCAA and a novel mutation of p.Val316Ile were detected. All of the pediatric-age patients (n = 13) were treated with ascorbic acid at a dose of 250-1000 mg/day. Conclusions Nine different HGD gene mutations with a novel one, p.Val316Ile, were detected. The most common mutation was p.Ser59AlafsX52 for the HGD gene followed by p.Gly161Arg and p.asn219Ser, which can be considered specific to the Turkish population.
Asunto(s)
Alcaptonuria/epidemiología , Biomarcadores/análisis , Factor de Crecimiento de Hepatocito/genética , Mutación , Adolescente , Adulto , Alcaptonuria/diagnóstico , Alcaptonuria/genética , Niño , Análisis Mutacional de ADN , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Turquía/epidemiología , Adulto JovenRESUMEN
QUESTION: Does Nitisinone prevent the clinical progression of the Alkaptonuria? FINDINGS: In this observational study on 39 patients, 2â¯mg of daily nitisinone inhibited ochronosis and significantly slowed the progression of AKU over a three-year period. MEANING: Nitisinone is a beneficial therapy in Alkaptonuria. BACKGROUND: Nitisinone decreases homogentisic acid (HGA), but has not been shown to modify progression of Alkaptonuria (AKU). METHODS: Thirty-nine AKU patients attended the National AKU Centre (NAC) in Liverpool for assessments and treatment. Nitisinone was commenced at V1 or baseline. Thirty nine, 34 and 22 AKU patients completed 1, 2 and 3â¯years of monitoring respectively (V2, V3 and V4) in the VAR group. Seventeen patients also attended a pre-baseline visit (V0) in the VAR group. Within the 39 patients, a subgroup of the same ten patients attended V0, V1, V2, V3 and V4 visits constituting the SAME Group. Severity of AKU was assessed by calculation of the AKU Severity Score Index (AKUSSI) allowing comparison between the pre-nitisinone and the nitisinone treatment phases. RESULTS: The ALL (sum of clinical, joint and spine AKUSSI features) AKUSSI rate of change of scores/patient/month, in the SAME group, was significantly lower at two (0.32⯱â¯0.19) and three (0.15⯱â¯0.13) years post-nitisinone when compared to pre-nitisinone (0.65⯱â¯0.15) (pâ¯<â¯.01 for both comparisons). Similarly, the ALL AKUSSI rate of change of scores/patient/month, in the VAR group, was significantly lower at one (0.16⯱â¯0.08) and three (0.19⯱â¯0.06) years post-nitisinone when compared to pre-nitisinone (0.59⯱â¯0.13) (pâ¯<â¯.01 for both comparisons). Combined ear and ocular ochronosis rate of change of scores/patient/month was significantly lower at one, two and three year's post-nitisinone in both VAR and SAME groups compared with pre-nitisinone (pâ¯<â¯.05). CONCLUSION: This is the first indication that a 2â¯mg dose of nitisinone slows down the clinical progression of AKU. Combined ocular and ear ochronosis progression was arrested by nitisinone.
Asunto(s)
Alcaptonuria/tratamiento farmacológico , Ciclohexanonas/administración & dosificación , Nitrobenzoatos/administración & dosificación , Ocronosis/tratamiento farmacológico , 4-Hidroxifenilpiruvato Dioxigenasa/metabolismo , Alcaptonuria/epidemiología , Alcaptonuria/metabolismo , Alcaptonuria/patología , Progresión de la Enfermedad , Femenino , Ácido Homogentísico/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Ocronosis/epidemiología , Ocronosis/metabolismo , Ocronosis/patología , Reino UnidoRESUMEN
OBJECTIVE: To analyze the results and follow up data of screening for newborn organic aciduria in Zhejiang province. METHODS: The results and follow-up data of 1 861 262 newborns from Zhejiang province undergoing screening for organic aciduria during January 2009 and December 2016 were retrospectively analyzed. The acylcarnitine spectrum in urine samples was detected by tandem mass spectrum (MS/MS) and the positive patients were confirmed by urine gas chromatography mass spectrometry and/or gene analysis. RESULTS: Ninety two cases of organic aciduria were confirmed with a prevalence of 1:20 200. Among 40 cases of methylmalonic academia (MMA), 13 (32.5%) were of MMA simple type and 27 (67.5%) were combined type. Genetic analysis showed 6 cases of MUT type and 1 case of CblB type out of 7 patients with MMA simple type, 10 cases of CblC and 1 case of CblF out of 11 patients with combined type, respectively. Six patients had propionic academia with a prevalence of 1:310 200, 7 had isovaleric academia (1:265 900), 6 had glutaric academia type 1 (1:310 200), 27 had 3-methylcrotonyl-CoA carboxylase deficiency (MCC, 1:68 900), 1 had 3-hydroxy-3-methylglutaric aciduria (1:1 861 300), 2 had ß-ketothiolase deficiency (1:960 600), and 3 had biotinidase deficiency/holocarboxylase synthetase deficiency (1:620 400). Thirty-one patients had a disease onset at neonatal period, and 15 at post-neonatal period. Thirty-three patients had brain involvements or cranial imaging disorders. Three patients with MMA had kidney diseases or heomlytic uremic syndrome, and 3 had myocardial impairments. Twenty patients died during the follow-up. CONCLUSIONS: MMA is the most common newborn organic aciduria in Zhejiang province. Except MCC, most organic aciduria may lead to metabolism decompensation, complications or even death.
Asunto(s)
Alcaptonuria , Tamizaje Neonatal , Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Alcaptonuria/terapia , China/epidemiología , Estudios de Seguimiento , Humanos , Recién Nacido , Prevalencia , Estudios Retrospectivos , Espectrometría de Masas en TándemAsunto(s)
Alcaptonuria/diagnóstico , Estenosis de la Válvula Aórtica/cirugía , Válvula Aórtica/patología , Ocronosis/diagnóstico , Esternón/patología , Anciano , Alcaptonuria/complicaciones , Alcaptonuria/epidemiología , Estenosis de la Válvula Aórtica/etiología , Color , Puente de Arteria Coronaria , Femenino , Implantación de Prótesis de Válvulas Cardíacas , Humanos , Hallazgos Incidentales , Ocronosis/etiología , Eslovaquia/epidemiologíaRESUMEN
Alkaptonuria (AKU) is caused by deficiency of the enzyme homogentisate 1,2 dioxygenase. It results in an accumulation of homogentisate which oxidizes spontaneously to benzoquinone acetate, a highly oxidant compound, which polymerises to a melanin-like structure, in a process called ochronosis. Asymptomatic during childhood, this accumulation will lead from the second decade of life to a progressive and severe spondylo-arthopathy, associated with multisystem involvement: osteoporosis/fractures, stones (renal, prostatic, gall bladder, salivary glands), ruptures of tendons/muscle/ligaments, renal failure and aortic valve disease. The pathophysiological mechanisms of AKU remain poorly understood, but recent advances lead us to reconsider the treatment strategy in AKU patients. Besides the supporting therapies (pain killers, anti-inflammatory drugs, physiotherapy, joints replacements and others), specific therapies have been considered (anti-oxidant, low protein diet, nitisinone), but clinical studies have failed to prove efficiency on the rheumatological lesions of the disease. Here we propose a treatment strategy for children and adults with AKU, based on a review of the latest findings on AKU and lessons from other aminoacipathies, especially tyrosinemias.
Asunto(s)
Alcaptonuria/tratamiento farmacológico , Adulto , Factores de Edad , Alcaptonuria/dietoterapia , Alcaptonuria/epidemiología , Antioxidantes/uso terapéutico , Niño , Ciclohexanonas/uso terapéutico , Humanos , Nitrobenzoatos/uso terapéutico , Ocronosis/dietoterapia , Ocronosis/tratamiento farmacológico , Ocronosis/epidemiología , Fenilalanina/administración & dosificación , Tirosina/administración & dosificaciónRESUMEN
Alkaptonuria (AKU) is an autosomal recessive disorder; caused by the mutations in the homogentisate 1, 2-dioxygenase (HGD) gene located on Chromosome 3q13.33. AKU is a rare disorder with an incidence of 1: 250,000 to 1: 1,000,000, but Slovakia and the Dominican Republic have a relatively higher incidence of 1: 19,000. Our study focused on studying the frequency of AKU and identification of HGD gene mutations in nomads. HGD gene sequencing was used to identify the mutations in alkaptonurics. For the past four years, from subjects suspected to be clinically affected, we found 16 positive cases among a randomly selected cohort of 41 Indian nomads (Narikuravar) settled in the specific area of Tamil Nadu, India. HGD gene mutation analysis showed that 11 of these patients carry the same homozygous splicing mutation c.87 + 1G > A; in five cases, this mutation was found to be heterozygous, while the second AKU-causing mutation was not identified in these patients. This result indicates that the founder effect and high degree of consanguineous marriages have contributed to AKU among nomads. Eleven positive samples were homozygous for a novel mutation c.87 + 1G > A, that abolishes an intron 2 donor splice site and most likely causes skipping of exon 2. The prevalence of AKU observed earlier seems to be highly increased in people of nomadic origin.
Asunto(s)
Alcaptonuria/epidemiología , Alcaptonuria/genética , Etnicidad/genética , Homogentisato 1,2-Dioxigenasa/genética , Alcaptonuria/patología , Secuencia de Bases , Cromatografía en Capa Delgada , Análisis Mutacional de ADN , Efecto Fundador , Genes Recesivos/genética , Pruebas Genéticas , Humanos , India/epidemiología , Datos de Secuencia Molecular , Mutación/genética , Prevalencia , Urinálisis/métodosRESUMEN
Alkaptonuria (AKU) is one of the four initially identified inborn errors of metabolism. The prevalence of AKU is unknown in Jordan. Therefore, a research project was started in April 2009 at the Faculty of Medicine/Mutah University in southern Jordan. The aims of the project were to identify people with AKU, to screen all family members with history of AKU, and to increase the awareness about the disease among health care professionals and the community in southern Jordan. Targeted family screening method was used to identify patients with AKU. In this paper, we present preliminary results of screening 17 families with history of AKU in a single village in southern region of Jordan. Forty cases with AKU were identified in this village (age range, 1-60 years). Early cases with AKU were diagnosed through out this study, two-third of patients (n = 28) were under the age of thirty. Interestingly, nine cases with AKU were identified in one family. Our experience suggests that for the identification of cases with AKU where consanguinity is common, the focus for screening should be extended to all family members. The prevalence of AKU among Jordanian is likely to be greater than the prevalence rates worldwide due to high rates of consanguineous marriages. Further studies and effective screening programs are needed to detect undiagnosed cases of AKU, to provide genetic counseling, and ultimately to prevent the occurrence of new cases of AKU in Jordan.
Asunto(s)
Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Adolescente , Adulto , Alcaptonuria/genética , Niño , Preescolar , Consanguinidad , Femenino , Humanos , Lactante , Jordania/epidemiología , Masculino , Persona de Mediana Edad , Linaje , PrevalenciaRESUMEN
Alkaptonuria is a rare metabolic disorder of tyrosine catabolism in which homogentisic acid (HGA) accumulates and is deposited throughout the spine, large joints, cardiovascular system, and various tissues throughout the body. In the cardiovascular system, pigment deposition has been described in the heart valves, endocardium, pericardium, aortic intima and coronary arteries. The prevalence of cardiovascular disease in patients with alkaptonuria varies in previous reports. We present a series of 76 consecutive adult patients with alkaptonuria who underwent transthoracic echocardiography between 2000 and 2009. A subgroup of 40 patients enrolled in a treatment study underwent non-contrast CT scans and these were assessed for vascular calcifications. Six of the 76 patients had aortic valve replacement. In the remaining 70 patients, 12 patients had aortic sclerosis and 7 patients had aortic stenosis. Unlike degenerative aortic valve disease, we found no correlation with standard cardiac risk factors. There was a modest association between the severity of aortic valve disease and joint involvement, however, we saw no correlation with urine HGA levels. Vascular calcifications were seen in the coronaries, cardiac valves, aortic root, descending aorta and iliac arteries. These findings suggest an important role for echocardiographic screening of alkaptonuria patients to detect valvular heart disease and cardiac CT to detect coronary artery calcifications.
Asunto(s)
Alcaptonuria/metabolismo , Alcaptonuria/patología , Estenosis de la Válvula Aórtica/patología , Sistema Cardiovascular/patología , Ácido Homogentísico/metabolismo , Tirosina/metabolismo , Calcificación Vascular/patología , Adulto , Anciano , Anciano de 80 o más Años , Alcaptonuria/complicaciones , Alcaptonuria/epidemiología , Estenosis de la Válvula Aórtica/complicaciones , Estenosis de la Válvula Aórtica/epidemiología , Ecocardiografía , Femenino , Ácido Homogentísico/orina , Humanos , Masculino , Persona de Mediana Edad , Pigmentos Biológicos/metabolismo , Tirosina/genética , Calcificación Vascular/complicaciones , Calcificación Vascular/epidemiología , Adulto JovenRESUMEN
Alkaptonuria (AKU) is an autosomal recessive disorder due to homogentisate 1,2-dioxygenase (HGD) deficiency in the liver and characterized by a triad of signs, according to chronology of appearance: homogentisic aciduria (HGA) or alkaptonuria, ochronosis then ochronotic arthropathy. This inborn error of metabolism is caused by mutations in the HGD gene. In this work we report observations of 96 AKU French patients from 81 families collected in the literature since 1882 and from our personal contribution since 1986, giving an incidence of the disease of around 1:680,000 (96/64.10(6)). As expected for an autosomal recessive disorder the main findings of this study were: a slight predominance of males (51/93, 54,8%) over females (42/93, 45,2%), a strong predominance of sibships with one affected individual (68/81, 84,0%) over sibships with two (11/81, 13.6%) and three(2/81, 2.4%) affected individuals. AKU families are scaterred among the French territory suggesting that most cases occured in non-consanguineous unions. Consanguinity was only found in five families. Other peculiarities of this study were (a) ten of these families have both parents from a foreign geographical origin: Poland(3), Italy(3), Portugal(2), Ukraine(1) and India(1) and four families with only one foreign parent (Algeria, Armenia, Serbia, UK), (b) HGD mutations were found in 23 families, (c) four of theses 96 patients were seen by us respectively 28, 29, 39 and 45 years after their report in the literature and (d) seven patients present cardiac and/or renal complications.
Asunto(s)
Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Adulto , Anciano , Alcaptonuria/terapia , Causalidad , Niño , Preescolar , Comorbilidad , Consanguinidad , Emigración e Inmigración , Femenino , Francia/epidemiología , Cardiopatías/epidemiología , Humanos , Incidencia , Lactante , Recién Nacido , Artropatías/epidemiología , Enfermedades Renales/epidemiología , Masculino , Persona de Mediana Edad , Ocronosis/epidemiología , Enfermedad de Parkinson/epidemiología , Distribución por SexoRESUMEN
Alkaptonuria (AKU) is due to excessive homogentisic acid accumulation in body fluids due to lack of enzyme homogentisate dioxygenase leading in turn to varied clinical manifestations mainly by a process of conversion of HGA to a polymeric melanin-like pigment known as ochronosis. A potential treatment, a drug called nitisinone, to decrease formation of HGA is available. However, successful demonstration of its efficacy in modifying the natural history of AKU requires an effective quantitative assessment tool. We have described two potential tools that could be used to quantitate disease burden in AKU. One tool describes scoring the clinical features that includes clinical assessments, investigations and questionnaires in 15 patients with AKU. The second tool describes a scoring system that only includes items obtained from questionnaires used in 44 people with AKU. Statistical analyses were carried out on the two patient datasets to assess the AKU tools; these included the calculation of Chronbach's alpha, multidimensional scaling and simple linear regression analysis. The conclusion was that there was good evidence that the tools could be adopted as AKU assessment tools, but perhaps with further refinement before being used in the practical setting of a clinical trial.
Asunto(s)
Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Ácido Homogentísico/metabolismo , Ocronosis/diagnóstico , Ocronosis/epidemiología , Índice de Severidad de la Enfermedad , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Alcaptonuria/tratamiento farmacológico , Alcaptonuria/enzimología , Causalidad , Estudios de Cohortes , Comorbilidad , Ciclohexanonas/uso terapéutico , Femenino , Homogentisato 1,2-Dioxigenasa/deficiencia , Humanos , Hipertensión/epidemiología , Masculino , Persona de Mediana Edad , Nitrobenzoatos/uso terapéutico , Ocronosis/tratamiento farmacológico , Ocronosis/enzimología , Dolor/epidemiología , Análisis de Regresión , Reproducibilidad de los Resultados , Distribución por Sexo , Fumar/epidemiología , Encuestas y CuestionariosRESUMEN
Alkaptonuria (AKU) is an autosomal recessive disorder caused by a deficiency of homogentisate 1,2 dioxygenase (HGD) and characterized by homogentisic aciduria, ochronosis, and ochronotic arthritis. The defect is caused by mutations in the HGD gene, which maps to the human chromosome 3q21-q23. AKU shows a very low prevalence (1:100,000-250,000) in most ethnic groups, but there are countries such as Slovakia and the Dominican Republic in which the incidence of this disorder rises to as much as 1:19,000. In this work, we summarize the genetic aspects of AKU in general and the distribution of all known disease-causing mutations reported so far. We focus on special features of AKU in Slovakia, which is one of the countries with an increased incidence of this rare metabolic disorder.
Asunto(s)
Alcaptonuria/epidemiología , Alcaptonuria/genética , Análisis Mutacional de ADN/métodos , Homogentisato 1,2-Dioxigenasa/genética , Mutación/genética , Alcaptonuria/diagnóstico , Alcaptonuria/enzimología , Mapeo Cromosómico/métodos , Cromosomas Humanos Par 3/genética , República Dominicana/epidemiología , Genética de Población , Genotipo , Salud Global , Homogentisato 1,2-Dioxigenasa/deficiencia , Homogentisato 1,2-Dioxigenasa/orina , Ácido Homogentísico/orina , Humanos , Incidencia , Artropatías/genética , Ocronosis/genética , Fenotipo , Eslovaquia/epidemiología , Topografía MédicaRESUMEN
Increased circulating homogentisic acid in body fluids occurs in alkaptonuria (AKU) due to lack of enzyme homogentisate dioxygenase leading in turn to conversion of HGA to a pigmented melanin-like polymer, known as ochronosis. The tissue damage in AKU is due to ochronosis. A potential treatment, a drug called nitisinone, to decrease formation of HGA is available. However, deploying nitisinone effectively requires its administration at the most optimal time in the natural history. AKU has a long apparent latent period before overt ochronosis develops. The rate of change of ochronosis and its consequences over time following its recognition has not been fully described in any quantitative manner. Two potential tools are described that were used to quantitate disease burden in AKU. One tool describes scoring the clinical features that includes clinical assessments, investigations and questionnaires in 15 patients with AKU. The second tool describes a scoring system that only includes items obtained from questionnaires in 44 people with AKU. Analysis of the data reveals distinct phases of the disease, a pre-ochronotic phase and an ochronotic phase. The ochronotic phase appears to demonstrate an earlier slower progression followed by a rapidly progressive phase. The rate of change of the disease will have implications for monitoring the course of the disease as well as decide on the most appropriate time that treatment should be started for it to be effective either in prevention or arrest of the disease.
Asunto(s)
Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Homogentisato 1,2-Dioxigenasa/deficiencia , 4-Hidroxifenilpiruvato Dioxigenasa/antagonistas & inhibidores , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alcaptonuria/tratamiento farmacológico , Alcaptonuria/enzimología , Artralgia/epidemiología , Artritis/enzimología , Artritis/epidemiología , Artritis/genética , Cartílago Articular/metabolismo , Causalidad , Estudios de Cohortes , Comorbilidad , Ciclohexanonas/uso terapéutico , Progresión de la Enfermedad , Femenino , Ácido Homogentísico/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Nitrobenzoatos/uso terapéutico , Ocronosis/enzimología , Ocronosis/epidemiología , Dolor/epidemiología , Encuestas y CuestionariosRESUMEN
The cardiovascular manifestations of alkaptonuria relate to deposition of ochronotic pigment within heart valves, endocardium, aortic intima and coronary arteries. We assessed 16 individuals with alkaptonuria for cardiovascular disease, including full electrocardiographic and echocardiographic assessment. The self reported prevalence of valvular heart disease and coronary artery disease was low. There was a significant burden of previously undiagnosed aortic valve disease, reaching a prevalence of over 40% by the fifth decade of life. The aortic valve disease was found to increase in both prevalence and severity with advancing age. In contrast to previous reports, we did not find a significant burden of mitral valve disease or coronary artery disease. These findings are important for the clinical follow-up of patients with alkaptonuria and suggest a role for echocardiographic surveillance of patients above 40 years old.
Asunto(s)
Alcaptonuria/epidemiología , Estenosis de la Válvula Aórtica/epidemiología , Válvula Aórtica/diagnóstico por imagen , Enfermedad de la Arteria Coronaria/epidemiología , Enfermedades de las Válvulas Cardíacas/epidemiología , Adulto , Distribución por Edad , Anciano , Válvula Aórtica/patología , Estenosis de la Válvula Aórtica/diagnóstico , Causalidad , Estudios de Cohortes , Comorbilidad , Enfermedad de la Arteria Coronaria/diagnóstico , Ecocardiografía/métodos , Femenino , Enfermedades de las Válvulas Cardíacas/diagnóstico , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Progress in research into rare diseases is challenging. This paper discusses strategies to identify individuals with the rare genetic disease alkaptonuria (AKU) within the general population. Strategies used included a questionnaire survey of general practitioners, a dedicated website and patient network contact, targeted family screening and medical conference targeting. Primary care physicians of the UK were targeted by a postal survey that involved mailing 11,151 UK GPs; the response rate was 18.2%. We have identified 75 patients in the UK with AKU by the following means: postal survey (23), targeted family screening (11), patient networks and the website (41). Targeting medical conferences (AKU, rare diseases, rheumatology, clinical biochemistry, orthopaedics, general practitioners) did not lead to new identification in the UK but helped identify overseas cases. We are now aware of 626 patients worldwide including newly identified non-UK people with AKU in the following areas: Slovakia (208), the rest of Europe (including Turkey) (79), North America (including USA and Canada) (110), and the rest of the world (154). A mechanism for identifying individuals with AKU in the general population-not just in the UK but worldwide-has been established. Knowledge of patients with AKU, both in the UK and outside, is often confined to establishing their location in a particular GP practice or association with a particular medical professional. Mere identification, however, does not always lead to full engagement for epidemiological research purposes or targeting treatment since further barriers exist.
Asunto(s)
Alcaptonuria/diagnóstico , Tamizaje Masivo/métodos , Tamizaje Masivo/normas , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alcaptonuria/epidemiología , Niño , Barreras de Comunicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Población , Reino Unido/epidemiología , Adulto JovenRESUMEN
Primary osteoarthritis (OA) of peripheral joints is a common disease mainly occurring after the age of 50. It is important to distinguish primary from secondary OA. Younger age at disease onset, rapid progression, unusual disease manifestations and co-morbidities are signs of secondary OA. This review outlines an important group of secondary OA. Hereditary metabolic diseases can exhibit joint involvement. For some of these diseases, correct diagnosis is critical, since appropriate therapy influences not only joint function and quality of life, but can also prevent relevant end-organ damage.
Asunto(s)
Errores Innatos del Metabolismo/diagnóstico , Errores Innatos del Metabolismo/genética , Osteoartritis/diagnóstico , Osteoartritis/genética , Adulto , Alcaptonuria/diagnóstico , Alcaptonuria/epidemiología , Alcaptonuria/genética , Animales , Niño , Condrocalcinosis/diagnóstico , Condrocalcinosis/epidemiología , Condrocalcinosis/genética , Estudios Transversales , Diagnóstico Diferencial , Síndrome de Gitelman/diagnóstico , Síndrome de Gitelman/epidemiología , Síndrome de Gitelman/genética , Hemocromatosis/diagnóstico , Hemocromatosis/epidemiología , Hemocromatosis/genética , Proteína de la Hemocromatosis , Degeneración Hepatolenticular/diagnóstico , Degeneración Hepatolenticular/epidemiología , Degeneración Hepatolenticular/genética , Antígenos de Histocompatibilidad Clase I/genética , Homocigoto , Humanos , Hipofosfatasia/diagnóstico , Hipofosfatasia/epidemiología , Hipofosfatasia/genética , Recién Nacido , Proteínas de la Membrana/genética , Errores Innatos del Metabolismo/epidemiología , Ocronosis/diagnóstico , Ocronosis/epidemiología , Ocronosis/genética , Osteoartritis/epidemiología , PenetranciaRESUMEN
This study was conducted to determine the prevalence of alkaptonuria in the UAE population and to identify the genotype of affected individuals. In a 3 stage sampling technique 2981 pupils from Government schools in Al Ain and private schools in Dubai were selected to take part in the study, of whom 2857 provided urine samples. Urine collected was analysed for homogentisic acid by gas chromatography-mass spectrometry. Genomic DNA was isolated from the white blood cells of all family members of the affected case following standard established protocols. Specific PRC primers were designed to amplify all 14 exons of the HGD gene with the flanking intronic sequences including the splice site sequences. 2857 children returned a viable urine sample, of which one was highly positive for homogentisic acid. All 12 members of this girl's family were studied and one, a 22 year old brother, was found to excrete HGA. Another, a sister who had not provided a urine sample, was discovered by genetic testing. There were no complaints of joint pain or other symptoms in any member of this family. Parents were first cousins. We found a single nucleotide deletion c.342delA, located in exon 3, which resulted in a frameshift at amino acid position 58 (p.Arg58fs or p.R58fs). Alkaptonuria may be more common than it is thought to be with an allele prevalence estimated at 0.0107 (95% CI 0.000392-0.03473). The R58fs mutation is old, perhaps having occurred several thousand years ago, and has spread over a large geographical area.